title: Optical coherence tomography angiography of type 3 neovascularisation in age-related macular degeneration after antiangiogenic therapy.
abstract: OBJECTIVE
  To assess the microvascular response of type 3 neovascularisation secondary to age-related macular degeneration (AMD) after antivascular endothelial growth factor (anti-VEGF) therapy using optical coherence tomography angiography (OCTA).
  
  
  METHODS
  Consecutive patients diagnosed with AMD and type 3 neovascularisation based on clinical examination, structural optical coherence tomography and fluorescein angiography when available were retrospectively evaluated. En face OCTA imaging (3×3 mm scans) with quantitative microvascular analysis was performed at baseline and after a single anti-VEGF intravitreal injection.
  
  
  RESULTS
  17 eyes of 14 patients underwent OCTA before and after anti-VEGF treatment. OCTA demonstrated significant regression of small calibre type 3 neovascular tufts in all eyes. Median lesion area was 0.061 mm2(range 0.003-0.198 mm2) at baseline and 0.009 mm2(range 0-0.085 mm2, p=0.0003) at follow-up. Cystoid macular oedema and/or subretinal fluid resolved in all cases after treatment. The type 3 lesions became undetectable with OCTA post-treatment in 5 of the 17 eyes. However, in 11 eyes, large feeder vessels were identified and remained unchanged after treatment.
  
  
  CONCLUSIONS
  The microvascular morphology of type 3 neovascularisation secondary to AMD was assessed at baseline and follow-up and showed significant regression in response to anti-VEGF therapy by OCTA. Quantitative OCTA analysis was also performed and confirmed remarkable regression in response to a single intravitreal anti-VEGF injection.
authors: Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.|Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors: Nopasak
authors: N
authors: Phasukkijwatana
authors: Vitreous Retina Macula Consultants of New York, New York, New York, USA.|LuEsther T Mertz Retinal Research Center, Manhattan, Eye, Ear and Throat Hospital, New York, New York, USA.|Singapore National Eye Center/Singapore Eye Research Institute, Singapore.
authors: Anna C S
authors: ACS
authors: Tan
authors: Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors: Xuejing
authors: X
authors: Chen
authors: Vitreous Retina Macula Consultants of New York, New York, New York, USA.|LuEsther T Mertz Retinal Research Center, Manhattan, Eye, Ear and Throat Hospital, New York, New York, USA.
authors: K Bailey
authors: KB
authors: Freund
authors: Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.|Greater Los Angeles VA Healthcare Center, Los Angeles, California, USA.
authors: David
authors: D
authors: Sarraf
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000150:complications / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab
keywords: Imaging; Macula; Neovascularisation